SCHIZOAMINE · The role of histamine dysfunction in sensory and cognitive deficits in schizophrenia
7РП — „Хора“ (Действия „Мария Кюри“)
- Период
- 2010-08-01 → 2012-01-31
- Финансиране от ЕС
- 129 431 €
- Участници
- 1
- Схема
- MC-IEF
Линиите свързват координатора с партньорите.
Накратко на български
Хистаминът в мозъка и влиянието на лекарството бетахистин върху работната памет и ученето се тестват чрез fMRI сканиране. Резултатите могат да помогнат за разбирането на сензорните и когнитивни затруднения при шизофренията и откриването на нови цели за лечение.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
The role of histamine dysfunction in sensory and cognitive deficits in schizophrenia
The overall aims and objectives of this project are to investigate the role of the histaminergic neurotransmitter system in sensory and cognitive symptoms characterizing schizophrenia. An established role of histamine provides a new drug target for the symptoms of schizophrenia. The objective is to increase histaminergic activity using combined H1-agonist and H3-antagonist in healthy volunteers, and measure the consequent performance on sensory and cognitive tasks and associated brain activity. Betahistine is a drug that has been used over 40 years to treat Meniere’s disease and acts as a H3-antagonist/H1-agonist. Betahistine enters the central nervous system where it increases histamine neurotransmission, and where it may be able to enhance cognitive functioning. Betahistine’s effects on psychomotor performance have been assessed in several studies. However, these studies found no change in performance after oral doses ranging from 48 mg to three times 72 mg. These studies have measured the effects 2 hours after the last or only dose, while betahistine has been shown to have a very short Tmax (30 min)(Obecure, Clinical Study Report, 2010). Therefore, the effects may have been missed by these studies. For the present studies it was chosen to administer betahistine twice with doses separated by 30 minutes. In the present study it is hypothesised that betahistine increases histamine neurotransmission and performance on tasks depending on frontal lobe activity and on performance, which is typically impaired in schizophrenia. To test this hypothesis healthy volunteers were recruited to perform tasks of working memory and associative learning after betahistine or placebo, while their brain activity was measured using fMRI.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
The aim of this study is to investigate the role of the neurotransmitter histamine in sensory and cognitive deficits (e.g. hearing voices, disturbed thinking and planning, memory problems) as they are observed in patients suffering from schizophrenia. The ideal location to conduct the study and to obtain a unique learning experience is at the Institute of Psychiatry, London United Kingdom, where staff comprises a mix of leading experts in the field of schizophrenia and experimental drug treatment as well as specialists in Magnetic Resonance Brain Imaging. The pharmacological treatment of psychotic symptoms including sensory and cognitive deficits as seen in schizophrenia remains partially unsuccessful due to side effects and treatment resistance. Therefore, new treatments are continuously developed by pharmaceutical companies. The neurotransmitter histamine is a promising target for new drugs. Histamine turnover in the brain has been suggested to be increased in schizophrenia which may underlie the positive symptoms. A decrease in histaminergic activity in the frontal cortex has been suggested to underlie the cognitive deficits. No attempts have been made until now to investigate the specific role of histamine in sensory and cognitive deficits typically seen in schizophrenics. To investigate this, I will assess the effects of increased histaminergic activity, by blocking the H3 receptor in healthy volunteers, on sensory gating and tasks of executive functioning (planning) and memory. Altered performance on such tasks would support the importance of histamine in schizophrenia and provides a model for new drug development in order to treat the sensory and cognitive deficits.
Оригинален текст от CORDIS (на английски).
Участници
- KING'S COLLEGE LONDON · LondonКоординаторОбединеното кралство
Връзки
Данни: CORDIS, © Европейски съюз